Peripheral muscle wasting in chronic obstructive pulmonary disease: Clinical relevance and mechanisms

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 9, 2001, Pages 1712-1717

  Debigaré, Richard ^b   Côté, Claude H ^b   Maltais, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MEDICAL RESEARCH; MUSCLE ATROPHY; MUSCLE METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0035509049     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.9.2104035     Document Type: Review

References (57)

1. Les cachexies respiratoires
2. Weight loss is a re-versible factor in the prognosis of chronic obstructive pulmonary disease
3. Wasting as independent risk factor for mortality in chronic heart failure
4. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants
5. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle
6. Skeletal muscle dysfunction in chronic obstructive pulmonary disease
7. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: Underlying mechanisms and therapy perspectives
8. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation
9. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease
10. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease
11. Corticosteroids contribute to muscle weakness in chronic airflow obstruction
12. Muscle strength, symptom intensity and exercise capacity in patients with cardiorespiratory disorders
13. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD
14. The daily energy expenditure in stable chronic obstructive pulmonary disease
15. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial
16. Biology of cachexia
17. Muscle wasting in emphysema
18. Wasting in HIV infection and AIDS
19. Pathophysiology of protein-energy wasting in chronic renal failure
20. Mechanism of muscle wasting
21. Cachexia
22. Role of TNF receptor I in protein turnover during cancer cachexia using gene knockout mice
23. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-kappa B
24. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy
25. Proteasome blockers inhibit protein breakdown in skeletal muscle after burn injury in rats
26. Parabiotic transfer of cancer anorexia/cachexia in male rats
27. NFκB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia
28. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice
29. The transcription factor NF-κB and human disease
30. Free radical-mediated effects on skeletal muscle protein in rats treated with Fe-nitrilotriacetate
31. Insulin-like growth factor (IGF-I) induces myotube hypertrophy associated with an increase in anaerobic glycolysis in a clonal skeletal-muscle cell model
32. Insulin-like growth factor I reduces ubiquitin and ubiquitin-conjugating enzyme gene expression but does not inhibit muscle proteolysis in septic rats
33. Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro
34. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting
35. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation
36. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease
37. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease
38. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis
39. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy
40. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation
41. Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease
42. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study
43. Cerretelli P. Effects of chronic hypoxia on muscle enzyme activities
44. Serum testosterone depression associated with hypoxia in respiratory failure
45. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease
46. Cellular adaptation in the diaphragm in chronic osbtructive pulmonary disease
47. Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the Neurolab space shuttle flight
48. Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD
49. Pulmonary emphysema decreases hamster skeletal muscle oxidative enzyme capacity
50. Metabolic and hemodynamic responses of the lower limb during exercise in patients with COPD
51. Myosin heavy chain isoform and ubiquitin protease mRNA expression after passive leg cycling in persons with spinal cord injury
52. The effect of salbutamol on performance in elite nonasthmatic athletes
53. Anticytokine approaches to the treatment of anorexia andcachexia
54. Wasting in cancer
55. Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: Mechanisms involved
56. 2-adrenergic agonist (clenbuterol)
57. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men